Interleukin 6 (IL-6) is an important cytokine that controls the cell survival and tumor growth. Hyperactive IL-6 may support cancer growth, particularly as it controls STAT3, which was shown to have an oncogenic role in most tumours. Many therapies are therefore designed to suppress IL-6 or STAT3.
But the situation is different in prostate cancer. Lukas Kenner’s research group has shown that, contrary to expectations; active STAT3 suppresses cell growth in prostate tumours. It activates the gene p14ARF, which blocks cell division and thus inhibits tumour growth.
“Using knockout mice, which are preclinical model organisms, we can link IL-6/Stat3 signalling to ARF, an important gene for cell cycle control and decisions to grow or to arrest. These findings have consequences for prostate cancer metastasis,” explained Jan Pencik, a PhD fellow in the lab, headed by Prof. Lukas Kenner.
For this reason, STAT3 and p14ARF are ideally suited to act as biomarkers for the prognosis of this disease. If these two factors are missing in tissue samples, the risk is massively increased that the tumour grows and forms metastases. According to Lukas Kenner, this is important, as the predictive power of these proteins as biomarkers is twice as good as the previous gold standard. As only about 10 % of patients with prostate cancer die from the disease, this can help to prevent unnecessary therapeutic interventions with severe side effects such as incontinence and impotence. A non-invasive nuclear medical test based on these findings might soon be able to replace the painful removal of tissue samples to be examined.
Receptor blockers can enhance prostate cancer
The reversed role of interleukin 6 as an inhibitor of prostate cancer has an additional significance. Blockade of interleukin 6 is used to treat other diseases, such as rheumatoid arthritis. According to Kenner, this means that therapies that block the IL-6 pathway may enhance the growth of prostate cancer. Thus, the drug that is used to treat inflammatory disease may exacerbate malignancies. “Applying IL-6/Stat3 blockers to clinical practice might be dangerous for patients with cancerous lesions, further studies are mandatory to assess the possibility of increased cancer risk right now“, says coauthor of this study, Prof Dr. Helmut Dolznig, also from the Medical University of Vienna. The study was financed mainly by the LBI-CR and the FWF. These results have just been published in the distinguished scientific journal Nature Communications.
Lukas Kenner is Head of the Department of Laboratory Animal Pathology in the Clinical Institute for Pathology in Medical University of Vienna. He is also Deputy Director at the Ludwig Boltzmann Institute for Cancer Research.
Service: Nature Communications
STAT3 regulated ARF expression suppresses prostate cancer metastasis – Jan Pencik, Michaela Schlederer, Wolfgang Gruber, Christine Unger, Steven M. Walker, Athena Chalaris, Isabelle J. Marié, Melanie R. Hassler, Tahereh Javaheri, Osman Aksoy, Jaine K. Blayney, Nicole Prutsch, Anna Skucha, Merima Herac, Oliver H. Krämer, Peter Mazal, Florian Grebien, Gerda Egger, Valeria Poli, Wolfgang Mikulits, Robert Eferl, Harald Esterbauer, Richard Kennedy, Falko Fend, Marcus Scharpf, Martin Braun, Sven Perner, David E. Levy, Tim Malcolm, Suzanne D. Turner, Andrea Haitel, Martin Susani, Ali Moazzami, Stefan Rose-John, Fritz Aberger, Olaf Merkel, Richard Moriggl, Zoran Culig, Helmut Dolznig & Lukas Kenner; Nature Communication DOI: 10.1038/ncomms8736
Five research clusters at Medical University of Vienna
Five research clusters are established at Medical University of Vienna. These provide the focus for basic and clinical research at Medical University of Vienna. The research clusters include medical imaging, cancer research/oncology, cardiovascular medicine, medical neurosciences and immunology. The present study falls under the cluster cancer research/oncology.